Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
90.62
+0.17 (0.19%)
Mar 24, 2026, 4:00 PM EDT - Market closed
Incyte Revenue
In the year 2025, Incyte had annual revenue of $5.14B with 21.22% growth. Incyte had revenue of $1.51B in the quarter ending December 31, 2025, with 27.84% growth.
Revenue (ttm)
$5.14B
Revenue Growth
+21.22%
P/S Ratio
3.51
Revenue / Employee
$1,807,750
Employees
2,844
Market Cap
18.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.14B | 900.03M | 21.22% |
| Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
| Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
| Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
| Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
| Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
| Dec 31, 2019 | 2.16B | 276.88M | 14.71% |
| Dec 31, 2018 | 1.88B | 345.67M | 22.50% |
| Dec 31, 2017 | 1.54B | 430.50M | 38.93% |
| Dec 31, 2016 | 1.11B | 351.97M | 46.70% |
| Dec 31, 2015 | 753.75M | 242.26M | 47.36% |
| Dec 31, 2014 | 511.50M | 508.45M | 16,696.72% |
| Dec 31, 2013 | 3.05M | -294.01M | -98.97% |
| Dec 31, 2012 | 297.06M | 202.60M | 214.50% |
| Dec 31, 2011 | 94.46M | -75.42M | -44.40% |
| Dec 31, 2010 | 169.88M | 160.61M | 1,733.55% |
| Dec 31, 2009 | 9.27M | 5.35M | 136.41% |
| Dec 31, 2008 | 3.92M | -30.52M | -88.62% |
| Dec 31, 2007 | 34.44M | 6.80M | 24.59% |
| Dec 31, 2006 | 27.64M | 19.80M | 252.32% |
| Dec 31, 2005 | 7.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
| Ionis Pharmaceuticals | 943.71M |
| Ascendis Pharma | 845.52M |
| BridgeBio Pharma | 502.08M |
INCY News
- 2 days ago - Incyte: An Undervalued Healthcare Gem - Seeking Alpha
- 4 days ago - Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Business Wire
- 7 days ago - Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue - Seeking Alpha
- 7 days ago - Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico - GlobeNewsWire
- 7 days ago - Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil - GlobeNewsWire
- 8 days ago - Incyte Stock: Multiple Potential Catalysts In 2026 And Beyond - Seeking Alpha
- 13 days ago - Incyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Incyte Corporation (INCY) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha